An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00027365 |
Recruitment Status
:
Completed
First Posted
: December 5, 2001
Last Update Posted
: May 4, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to see if the investigational vaccines NefTat and gp120w61d are safe and tolerable in humans and to see how the immune system responds to the vaccines.
There have been advances in the treatment and prevention of HIV, but the spread of HIV/AIDS is getting worse. HIV/AIDS is the main infectious cause of death in the world. A vaccine to prevent HIV disease is the best way to try to deal with this situation. Several vaccine products have been tested, but only 2 are still in trial. There is a need for a new product.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Biological: Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A Biological: NefTat Drug: AS02A Adjuvant Biological: gp120W61D | Phase 1 |
Despite recent advances in the treatment and prevention of HIV disease, the epidemic is worsening throughout most of the world. HIV/AIDS is the leading cause of death in sub-Saharan Africa and the leading infectious cause of death in the world. An effective and inexpensive vaccine to prevent HIV disease remains as the best option to try to deal with this expanding epidemic. A number of vaccine products have been tested; however, only 2 have progressed to a Phase III trial, underscoring the need for new vaccine strategies.
Prior to study entry, participants have their risk status for HIV infection determined by a series of questions. Further eligibility is determined by results of physical exam, laboratory tests, and further questions. Blood is drawn on each study visit. Participants are assigned randomly to 1 of 4 study groups:
Group I: NefTat or placebo. Groups II, III, and IV: NefTat and gp120 or placebo. Each group receives a different concentration of gp120.
All immunizations are admixed with AS02A adjuvant. Vaccinations are administered intramuscularly at 3 time points (entry, 1 month, and 3 months). Product safety and immunogenicity are performed at designated time points; participants have about 11 clinic visits.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 84 participants |
Masking: | Double |
Primary Purpose: | Prevention |
Official Title: | A Phase I Safety and Immunogenicity Trial of a Combination Vaccine (NefTat and gp120w61d) Formulated With AS02A (GlaxoSmithKline Biologicals) Given Intramuscularly in HIV-1 Uninfected Adult Participants |
Actual Study Completion Date : | June 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
Participants may be eligible for this study if they:
- Are between 18 and 60 years of age.
- Are in good general health and meet laboratory test requirements.
- Have a CD4 count of 400 or more cells/mm3.
- Agree to use at least 1 of the following methods of contraception for at least 21 days before enrollment until the last protocol visit: condoms (male or female) with or without a spermicide, diaphragm or cervical cap with spermicide, IUD, or hormonal-based therapy (applies to women who are able to have children).
- Have access to a participating site and are willing to have follow-up for the entire study (12 months).
- Answer questions about their understanding of the study.
- Do not have hepatitis B or C.
- Are HIV-uninfected.
Exclusion Criteria
Participants may not be eligible for this study if they:
- Are pregnant or breast-feeding.
- Have recently received a vaccine.
- Have used experimental agents within 30 days before enrollment.
- Have received HIV vaccines or placebo in a previous HIV vaccine study.
- Have received blood products 120 days before HIV screening.
- Have received immunoglobulin (antibodies) 60 days before HIV screening.
- Have serious reactions to vaccines.
- Have problems with their immune system.
- Have cancer.
- Have used drugs that affect the immune system within the past 6 months.
- Have diabetes.
- Have a thyroid disease.
- Have unstable asthma.
- Are taking anti-tuberculosis drugs.
- Have seizures.
- Have a bleeding disorder.
- Have had their spleen removed.
- Have angioedema (a certain type of body tissue swelling).
- Have active syphilis.
- Have high blood pressure (unless controlled by medication).
- Have mental or emotional problems that make them unsuitable for the study.
- Have any medical, mental, or social condition; job responsibilities; or other responsibility that, in the opinion of the doctor, would interfere with the study.
- Have reactions to components of the vaccines.
- Are at high risk for contracting HIV.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00027365
United States, Alabama | |
Alabama Vaccine CRS | |
Birmingham, Alabama, United States, 35294 | |
United States, California | |
San Francisco Vaccine and Prevention CRS | |
San Francisco, California, United States, 94102 | |
United States, Maryland | |
Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research, Project SAVE-Baltimore | |
Baltimore, Maryland, United States, 21205 | |
Project Brave HIV Vaccine CRS | |
Baltimore, Maryland, United States | |
United States, Massachusetts | |
Brigham and Women's Hosp. CRS | |
Boston, Massachusetts, United States, 02115 | |
Fenway Community Health Clinical Research Site (FCHCRS) | |
Boston, Massachusetts, United States, 02115 | |
United States, Missouri | |
Saint Louis Univ. School of Medicine, HVTU | |
Saint Louis, Missouri, United States, 63110 | |
United States, New York | |
NY Blood Ctr./Bronx CRS | |
Bronx, New York, United States, 10456 | |
NY Blood Ctr./Union Square CRS | |
New York, New York, United States, 10021 | |
HIV Prevention & Treatment CRS | |
New York, New York, United States | |
Univ. of Rochester HVTN CRS | |
Rochester, New York, United States, 14642 | |
United States, Rhode Island | |
Miriam Hospital's HVTU | |
Providence, Rhode Island, United States, 02906 | |
United States, Tennessee | |
Vanderbilt Vaccine CRS | |
Nashville, Tennessee, United States, 37232 | |
United States, Virginia | |
Infectious Diseases Physicians, Inc. | |
Annandale, Virginia, United States | |
United States, Washington | |
FHCRC/UW Vaccine CRS | |
Seattle, Washington, United States |
Study Chair: | Tom Evans |
Publications of Results:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00027365 History of Changes |
Other Study ID Numbers: |
HVTN 041 10196 ( Registry Identifier: DAIDS ES Registry Number ) |
First Posted: | December 5, 2001 Key Record Dates |
Last Update Posted: | May 4, 2012 |
Last Verified: | May 2012 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
HIV Seronegativity HIV Preventive Vaccine Injections, Intramuscular HIV Antibodies HIV-1 HIV Envelope Protein gp120 |
Gene Products, tat AIDS Vaccines Neutralization Tests Vaccines, Combined AIDS Seronegativity Gene Products, nef |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |